Bipolar II disorder : epidemiology, diagnosis and management.
Bipolar II disorder (BP-II) is defined, by DSM-IV, as recurrent episodes of depression and hypomania. Hypomania, according to DSM-IV, requires elevated (euphoric) and/or irritable mood, plus at least three of the following symptoms (four if mood is only irritable): grandiosity, decreased need for sleep, increased talking, racing thoughts, distractibility, overactivity (an increase in goal-directed activity), psychomotor agitation and excessive involvement in risky activities. This observable change in functioning should not be severe enough to cause marked impairment of social or occupational functioning, or to require hospitalisation. The distinction between BP-II and bipolar I disorder (BP-I) is not clearcut. The symptoms of mania (defining BP-I) and hypomania (defining BP-II) are the same, apart from the presence of psychosis in mania, and the distinction is based on the presence of marked impairment associated with mania, i.e. mania is more severe and may require hospitalisation. This is an unclear boundary that can lead to misclassification; however, the fact that hypomania often increases functioning makes the distinction between mania and hypomania clearer. BP-II depression can be syndromal and subsyndromal, and it is the prominent feature of BP-II. It is often a mixed depression, i.e. it has concurrent, usually subsyndromal, hypomanic symptoms. It is the depression that usually leads the patient to seek treatment.DSM-IV bipolar disorders (BP-I, BP-II, cyclothymic disorder and bipolar disorder not otherwise classified, which includes very rapid cycling and recurrent hypomania) are now considered to be part of the 'bipolar spectrum'. This is not included in DSM-IV, but is thought to also include antidepressant/substance-associated hypomania, cyclothymic temperament (a trait of highly unstable mood, thinking and behaviour), unipolar mixed depression and highly recurrent unipolar depression.BP-II is underdiagnosed in clinical practice, and its pharmacological treatment is understudied. Underdiagnosis is demonstrated by recent epidemiological studies. While, in DSM-IV, BP-II is reported to have a lifetime community prevalence of 0.5%, epidemiological studies have instead found that it has a lifetime community prevalence (including the bipolar spectrum) of around 5%. In depressed outpatients, one in two may have BP-II. The recent increased diagnosing of BP-II in research settings is related to several factors, including the introduction of the use of semi-structured interviews by trained research clinicians, a relaxation of diagnostic criteria such that the minimum duration of hypomania is now less than the 4 days stipulated by DSM-IV, and a probing for a history of hypomania focused more on overactivity (increased goal-directed activity) than on mood change (although this is still required for a diagnosis of hypomania). Guidelines on the treatment of BP-II are mainly consensus based and tend to follow those for the treatment of BP-I, because there have been few controlled studies of the treatment of BP-II. The current, limited evidence supports the following lines of treatment for BP-II. Hypomania is likely to respond to the same agents useful for mania, i.e. mood-stabilising agents such as lithium and valproate, and the second-generation antipsychotics (i.e. olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole). Hypomania should be treated even if associated with overfunctioning, because a depression often soon follows hypomania (the hypomania-depression cycle). For the treatment of acute BP-II depression, two controlled studies of quetiapine have not found clearcut positive effects. Naturalistic studies, although open to several biases, have found antidepressants in acute BP-II depression to be as effective as in unipolar depression; however, one recent large controlled study (mainly in patients with BP-I) has found antidepressants to be no more effective than placebo. Results from naturalistic studies and clinical observations on mixed depression, while in need of replication in controlled studies, indicate that antidepressants may worsen the concurrent intradepression hypomanic symptoms. The only preventive treatment for both depression and hypomania that is supported by several, albeit older, controlled studies is lithium. Lamotrigine has shown some efficacy in delaying depression recurrences, but there have also been several negative unpublished studies of the drug in this indication.
Benazzi
Franco
F
Hecker Psychiatry Research Center, a University of California at San Diego (USA) Collaborating Center at Forli, Italy. FrancoBenazzi@FBenazzi.it
D000328:Adult; D001714:Bipolar Disorder / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000523:psychology / Q000628:therapy*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000523:psychology; D003937:Diagnosis, Differential; D006801:Humans; D011569:Psychiatric Status Rating Scales
Arch Gen Psychiatry. 1997 Apr;54(4):329-36
9107149
Arch Gen Psychiatry. 1982 Sep;39(9):1065-9
6810839
Arch Gen Psychiatry. 1982 Nov;39(11):1344-5
6814397
J Affect Disord. 2006 Apr;91(2-3):133-8
16458364
Am J Psychiatry. 1983 Sep;140(9):1127-33
6351641
J Affect Disord. 2005 Feb;84(2-3):187-96
15708416
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
15939837
J Clin Psychopharmacol. 1998 Oct;18(5):414-7
9790160
Biol Psychiatry. 2004 Jul 1;56(1):54-60
15219473
J Affect Disord. 2003 Jan;73(1-2):65-74
12507739
J Affect Disord. 2006 Jun;92(2-3):205-14
16516304
Bipolar Disord. 2004 Oct;6(5):440-1
15383139
Arch Gen Psychiatry. 1976 Jan;33(1):117-20
1108832
Arch Gen Psychiatry. 2005 Dec;62(12):1322-30
16330720
J Clin Psychiatry. 2006 Aug;67(8):1246-52
16965203
Psychopathology. 2005 Sep-Oct;38(5):268-72
16179813
Arch Gen Psychiatry. 1998 Jan;55(1):27-32
9435757
J Affect Disord. 2006 Dec;96(3):233-7
16427137
Psychother Psychosom. 2007;76(1):40-6
17170562
J Affect Disord. 2006 Dec;96(3):183-7
16427131
Am J Psychiatry. 2006 Feb;163(2):210-6
16449473
Am J Psychiatry. 1998 May;155(5):638-45
9585715
J Affect Disord. 2006 Dec;96(3):259-69
16997383
Am J Psychiatry. 2006 Feb;163(2):232-9
16449476
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):68-74
16019119
J Affect Disord. 1998 Sep;50(2-3):153-62
9858075
J Affect Disord. 1997 Apr;43(2):163-6
9165385
Am J Psychiatry. 1992 Dec;149(12):1633-44
1359799
J Clin Psychiatry. 2000 Sep;61(9):630-7
11030482
J Affect Disord. 2005 Feb;84(2-3):167-78
15708414
Arch Gen Psychiatry. 2006 Mar;63(3):246-8
16520428
Bipolar Disord. 2006 Oct;8(5 Pt 2):596-617
17042833
Acta Psychiatr Scand. 1993 Apr;87(4):279-84
8488750
Arch Gen Psychiatry. 1991 Sep;48(9):807-12
1929771
Am J Psychiatry. 2005 Nov;162(11):2152-61
16263857
Psychiatry Res. 2004 Jul 15;127(3):247-57
15296824
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1279-85
15588754
J Affect Disord. 2003 Jan;73(1-2):123-31
12507745
J Affect Disord. 2003 Jan;73(1-2):133-46
12507746
Arch Gen Psychiatry. 2003 Mar;60(3):261-9
12622659
Am J Psychiatry. 1982 Jun;139(6):747-52
6805339
Lancet. 2007 Mar 17;369(9565):935-45
17368155
Bipolar Disord. 2004 Aug;6(4):305-13
15225148
J Clin Psychiatry. 2004 Mar;65(3):432-41
15096085
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1043-50
16682104
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):97-103
16978754
J Clin Psychiatry. 2005 Jul;66(7):914-21
16013908
Am J Psychiatry. 1988 Feb;145(2):179-84
3341463
J Clin Psychiatry. 2003 Apr;64(4):403-7
12716240
Psychother Psychosom. 2005;74(1):61-2
15627859
J Affect Disord. 2001 Dec;67(1-3):123-32
11869759
J Clin Psychiatry. 2000 Nov;61(11):841-50
11105737
J Affect Disord. 2003 Jan;73(1-2):49-57
12507737
Am J Psychiatry. 2006 Nov;163(11):1905-17
17074942
Arch Gen Psychiatry. 2006 Oct;63(10):1130-8
17015815
J Affect Disord. 2006 May;92(1):45-54
16488021
J Clin Psychiatry. 2005 Jun;66(6):693-704
15960561
J Affect Disord. 2003 Jan;73(1-2):87-98
12507741
Eur Psychiatry. 2007 Mar;22(2):99-103
17129709
Acta Psychiatr Scand. 2004 Dec;110(6):401-7
15521823
World J Biol Psychiatry. 2003 Oct;4(4):166-71
14608587
J Affect Disord. 2005 Feb;84(2-3):259-66
15708424
J Clin Psychiatry. 2006 May;67(5):712-9
16841620
Compr Psychiatry. 2004 Nov-Dec;45(6):441-6
15526254
Psychopathology. 2007;40(1):54-60
17065838
Am J Psychiatry. 2004 Jul;161(7):1264-9
15229060
Can J Psychiatry. 2006 Jan;51(1):9-16
16491979
J Clin Psychiatry. 1999 Feb;60(2):79-88
10084633
Arch Gen Psychiatry. 1982 Oct;39(10):1157-67
7125846
J Affect Disord. 2001 Dec;67(1-3):213-9
11869771
J Clin Psychiatry. 2006 Jul;67(7):1025-33
16889444
J Affect Disord. 2003 Jan;73(1-2):33-8
12507735
J Affect Disord. 2006 Aug;94(1-3):111-9
16701902
Psychother Psychosom. 2007;76(2):70-6
17230047
J Affect Disord. 2005 Oct;88(2):217-33
16125784
Arch Gen Psychiatry. 2006 Oct;63(10):1139-48
17015816
J Clin Psychiatry. 2006;67 Suppl 11:18-21
17029492
J Clin Psychiatry. 2006 Mar;67(3):355-62
16649820
J Affect Disord. 2003 Jan;73(1-2):113-22
12507744
World J Biol Psychiatry. 2007;8(2):105-11
17455103
Arch Gen Psychiatry. 1995 Feb;52(2):114-23
7848047
Am J Psychiatry. 1991 Jul;148(7):910-6
2053632
J Clin Psychopharmacol. 1998 Dec;18(6):435-40
9864074
J Affect Disord. 1997 Oct;46(1):73-7
9387089
Int J Neuropsychopharmacol. 2003 Jun;6(2):127-37
12890306
Acta Psychiatr Scand. 2003 Jul;108(1):4-14
12807371
Am J Psychiatry. 2001 Aug;158(8):1265-70
11481161
Compr Psychiatry. 2004 Mar-Apr;45(2):77-82
14999656
Compr Psychiatry. 2005 Nov-Dec;46(6):399-404
16275206
Can J Psychiatry. 2002 Mar;47(2):125-34
11926074
Arch Gen Psychiatry. 2006 Feb;63(2):175-83
16461861
Br J Psychiatry. 2006 Aug;189:124-31
16880481
Br J Psychiatry. 2006 Oct;189:346-53
17012658
Eur Psychiatry. 2006 Jun;21(4):274-9
16675205
J Affect Disord. 2005 Feb;84(2-3):149-57
15708412
Eur Arch Psychiatry Neurol Sci. 1984;234(1):13-20
6333343
Acta Psychiatr Scand. 2004 Nov;110(5):374-82
15458561
Am J Psychiatry. 2004 Sep;161(9):1537-47
15337640
Psychol Med. 2006 May;36(5):619-27
16438739
J Affect Disord. 2005 Feb;84(2-3):225-32
15708420
Compr Psychiatry. 2003 Jan-Feb;44(1):21-7
12524632
J Affect Disord. 2003 Jan;73(1-2):19-32
12507734
Bipolar Disord. 2005 Oct;7(5):441-8
16176437
Neuropsychopharmacology. 2003 Jul;28(7):1374-82
12784116
Psychiatry Clin Neurosci. 2005 Oct;59(5):570-5
16194260
J Clin Psychiatry. 2006 Jan;67(1):48-55
16426088
J Clin Psychiatry. 2007 Jan;68(1):102-10
17284137
Arch Gen Psychiatry. 1994 Jan;51(1):8-19
8279933
Am J Psychiatry. 1970 Jan;126(7):983-7
5409569
Am J Psychiatry. 1999 Mar;156(3):426-30
10080559
Arch Gen Psychiatry. 2002 Jun;59(6):530-7
12044195
Am J Psychiatry. 2005 Jul;162(7):1351-60
15994719
Int Clin Psychopharmacol. 1999 Sep;14(5):283-5
10529071
J Affect Disord. 2005 Feb;84(2-3):159-66
15708413
Br J Psychiatry. 2005 Jul;187:87-8
15994577
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Oct;26(6):1105-11
12452532
Bipolar Disord. 2000 Sep;2(3 Pt 2):281-93
11249806
J Affect Disord. 2003 Jan;73(1-2):199-205
12507752
Psychol Med. 1988 Feb;18(1):141-53
3363034
Arch Gen Psychiatry. 2002 Aug;59(8):736-40
12150650
Bipolar Disord. 2003 Dec;5(6):421-33
14636365
J Clin Psychopharmacol. 2006 Dec;26(6):600-9
17110817
J Affect Disord. 2005 Mar;85(1-2):3-16
15780671
J Affect Disord. 2003 Jan;73(1-2):7-18
12507733
Am J Psychiatry. 2003 Jan;160(1):4-12
12505793
J Clin Psychiatry. 2003 Sep;64(9):1013-24
14628976
Arch Gen Psychiatry. 2003 Apr;60(4):392-400
12695317
Br J Psychiatry. 2007 Mar;190:189-91
17329735
Psychother Psychosom. 2007;76(2):65-9
17230046
Psychol Med. 2004 May;34(4):597-611
15099415
J Affect Disord. 2002 Apr;68(2-3):203-13
12063148
N Engl J Med. 2007 Apr 26;356(17):1711-22
17392295
J Affect Disord. 2005 Feb;84(2-3):141-7
15708411
Am J Psychiatry. 1995 Mar;152(3):385-90
7864264
Compr Psychiatry. 2004 May-Jun;45(3):168-74
15124146
Am J Psychiatry. 2006 Feb;163(2):313-5
16449487
Am J Psychiatry. 2006 Sep;163(9):1644; author reply 1644-5
16946197
Am J Psychiatry. 2003 Jul;160(7):1263-71
12832240
J Affect Disord. 2004 Feb;78(2):149-52
14706725
J Clin Psychiatry. 2004 May;65(5):627-33
15163248
Arch Gen Psychiatry. 2003 Sep;60(9):914-20
12963673
J Affect Disord. 2000 Sep;59(3):225-9
10854639
J Affect Disord. 2003 Jan;73(1-2):39-47
12507736
Aust N Z J Psychiatry. 2005 Aug;39(8):726-9
16050927
Eur Arch Psychiatry Clin Neurosci. 2006 Feb;256(1):1-16
16078087
Clin Neuropharmacol. 1990;13 Suppl 1:S66-70
2116228
Am J Psychiatry. 1978 May;135(5):570-2
347953
Acta Psychiatr Scand. 2003 Apr;107(4):268-74
12662249
J Affect Disord. 2006 Dec;96(3):189-96
16427136
J Affect Disord. 2006 Dec;96(3):197-205
16824616
Int Clin Psychopharmacol. 2007 Mar;22(2):93-100
17293709
J Affect Disord. 2001 Dec;67(1-3):105-14
11869757
Arch Gen Psychiatry. 2005 Oct;62(10):1089-96
16203954
Am J Psychiatry. 2000 Nov;157(11):1873-5
11058490
Compr Psychiatry. 2005 May-Jun;46(3):159-66
16021584
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):985-91
14499315
Am J Psychiatry. 2003 Dec;160(12):2134-40
14638583
Bipolar Disord. 2005 Oct;7(5):456-64
16176439
Arch Gen Psychiatry. 1984 Nov;41(11):1096-104
6437366
Pharmakopsychiatr Neuropsychopharmakol. 1976 May;9(3):100-7
981326
J Affect Disord. 2005 Feb;84(2-3):133-9
15708410
J Affect Disord. 2005 Apr;85(3):245-58
15780694
Psychiatr Clin North Am. 2002 Dec;25(4):699-712, v
12462856